LYSOPHOSPHATIDIC ACID (LPA) is a biologically active lipid mediator. LPA has been shown to induce proliferation, migration, and metastasis of tumor cells (1, 20) . LPA binds to G protein-coupled receptors (LPA 1 , LPA 2 , and LPA 3 ) to induce these effects (4) , which are mediated through both the ERK and Akt pathways (4, 20, 30) . LPA receptors (LPARs) are widely expressed in many tissues, including ovarian tissue (37) , but the exact roles of each receptor are still being explored (46) .
LPA is found in plasma at relatively low concentrations but is present at higher concentrations in ascites fluid from ovarian cancer patients (44) . Ovarian cancer cells have been shown to produce LPA (32) . LPA is thought to play an important role in the metastatic processes involved with cancer progression. It has been demonstrated that LPA increases proliferation in various carcinoma cell lines, including prostate cancer cells (40) and ovarian cancer cells (15) . There are many enzymes involved in the production and degradation of LPA. Lysophospholipase D (lyso-PLD) and autotaxin (a form of lyso-PLD) cleave the choline head group from lysophosphatidylcholine to form LPA (36, 42) . Phospholipase D (PLD), of which there are two isoforms, PLD 1 and PLD 2 , hydrolyzes phosphatidylcholine to form phosphatidic acid (PA) (11) ; PA can then be converted to LPA by phospholipase A (PLA) isoforms (21, 43) . LPA can be dephosphorylated to monoacylglycerol by lipid phosphate phosphatases (LPPs) (23) . Although PLD isoforms have been implicated in LPA generation in ovarian cancer cells stimulated with nucleotide receptor agonists (21) and LPA (8) , their roles in growth factor-mediated LPA production have not been examined. The current study focuses on the role of PLD 2 , an agonist-activated enzyme (11) , in epidermal growth factor (EGF)-stimulated LPA production.
EGF, a polypeptide growth factor, binds to the EGF receptor (EGFR), a transmembrane protein tyrosine kinase. EGF stimulates proliferation of ovarian cancer cells and other types of carcinoma cells (3) . Growth stimulation by EGF is mediated in part by the ERK and Akt pathways, as is also the case for LPA.
LPA can stimulate transactivation of the EGFR in some cell types (22, 38) . LPA can activate matrix metalloproteases, which cleave pro-EGF from the membrane to release active ligand (26) . Intracellular signaling molecules, such as phospholipase C and PLD, have also been suggested as mediators of LPA-induced transactivation of receptor tyrosine kinases (6, 14) . Conversely, some growth factors and cytokines can activate LPA production, resulting in transactivation of LPA receptors (40, 47) . EGF and LPA have been shown to induce common signaling pathways, such as ERK and Akt, which lead to growth and proliferation of tumor cells (30, 31, 40) . Thus, these two agonists activate similar downstream signaling events, and some reports suggest that LPA-induced mitogenic signaling is mediated primarily through EGFR transactivation (12, 18) . However, it is not yet clear whether EGFR transactivation is responsible for all LPA-mediated mitogenic signaling events. Of particular importance to the current study, it has not been tested whether the reverse cross-talk occurs, i.e., whether EGF can stimulate activation of LPA receptors. Our laboratory has shown that other mitogens can stimulate LPA production in various cell types (40, 47) .
In this study we used OVCAR3 and SKOV3 adenocarcinoma cells, two well-characterized human ovarian cancer cell lines, as models to examine the mechanisms involved in EGF-induced LPA production. Stimulation of cells with EGF increases LPA levels in the medium. This response can be inhibited by blocking either EGFR activation or LPAR signaling. Overexpression of PLD 2 increases LPA production, while knockdown of PLD 2 blocks EGF-induced LPA production. The results show that EGF activates PLD 2 , that PLD 2 is involved in the production of LPA, and that bidirectional cross-talk can occur between EGF and LPA receptors. Cell culture. SKOV3 and OVCAR3 cells, obtained from American Type Culture Collection (Manassas, VA), were maintained in RPMI 1640 medium (Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA), and McCoy's 5A medium supplemented with 10% fetal bovine serum, respectively. All cells were grown at 37°C in 5% CO 2-95% air on standard tissue culture plastic. Cells were serum starved by incubation in serum-free medium for 12-24 h before the start of the experiments.
MATERIALS AND METHODS

Materials
Isotopic method for LPA analysis. LPA production in cells and medium was assessed as described previously (41) . Briefly, cells were grown in six-well plates and metabolically labeled with 5 Ci/well [ 3 H]palmitic acid, in serum-free medium, for 12-24 h. Before treatment, the labeled cells were incubated in Dulbecco's modified Eagle's medium supplemented with 10 mM HEPES (pH 7.5) and incubated in this medium at 37°C for 1 h. Agonists and/or antagonists were then added for the indicated times. Following treatment, methanol/HCl and chloroform were used to extract lipids from cells and medium, as previously described (12) . Lipids were dried under nitrogen and resuspended in chloroform/methanol. Oleoyl (18:1)-LPA was added to each tube as a standard. Thin-layer chromatography, on an oxalic acid-impregnated plate, was used to separate the lipids. The LPA standard was visualized by iodine staining. [ 3 H]-labeled lipids were then localized by using autoradiography after the plates were sprayed with Enhance (PerkinElmer Life Sciences, Boston, MA). The LPA band and the remainder of the lane were separately scraped from the TLC plate; radioactivity was quantified using liquid scintillation spectrometry.
Immunoblotting. Whole cell extracts were prepared from OVCAR3 cells using a lysis buffer containing 1 M HEPES, 1 M NaCl, 0.1 M EGTA, 1 M ␤-glycerophosphate, 0.2 M Na-pyrophosphate, 0.01 M sodium orthovanadate, 1% Triton X-100, 0.1 M PMSF, aprotinin (10 mg/ml), and leupeptin (10 mg/ml). Protein concentrations were determined using Coomassie blue reagent (Pierce Chemical, Rockford, IL). Equal amounts of protein (100 g) were loaded on each lane of a 10% Laemmli polyacrylamide gel. Proteins were separated by SDS-PAGE and transferred to nitrocellulose. Blots were developed using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ).
Transfection with PLD 2 expression vector. Cells were seeded and grown to ϳ40% confluence. Cells were then transfected with a hemagglutinin (HA)-tagged PLD 2 expression vector (16) using Lipofectamine 2000 (LF2000). Briefly, cells were transfected for 48 h with 1 g of DNA and were then serum-starved for 12 h before experimentation.
Incubation with small interfering RNA for PLD 2. Cells were seeded and grown to ϳ40% confluence. Cells were then incubated with predesigned small interfering RNAs (siRNAs) for PLD 2 from Ambion, according to the manufacturer's directions. Briefly, cells were incubated with 20 nM siRNA for PLD 2, using LF2000, for 48 h. Cells were then serum starved before experimentation.
In vitro membrane PLD activity assay. Serum-starved cells were incubated with the desired agonist and were then harvested at 4°C. Cells were lysed by sonication; membranes were collected by centrifugation at 100,000 g. Cellular membranes were incubated with 0.9% butanol and BODIPY-phosphatidylcholine for 60 min at 30°C as previously described (41) . The samples were spotted on plasticbacked silica gel TLC plates and developed with methanol-chloroform-water-acetic acid (45:45:10:2, vol/vol). Products were visualized using ultraviolet light and phosphoimaging. The retardation factor (R f) Fig. 1 . Effects of epidermal growth factor (EGF) on lysophosphatidic acid (LPA) production in ovarian cancer cells. OVCAR3 and SKOV3 cells were serum starved and metabolically labeled with [ 3 H]palmitic acid for 18 h and then stimulated with 10 nM EGF for times from 5 to 120 min. Medium was harvested, and the lipids were separated using TLC. Liquid scintillation counting was used to quantify LPA and other total lipids. LPA is represented as a percentage of the total lipid recovered from medium. The values shown were normalized to the untreated control and represent means Ϯ SE for triplicate wells of cells (**P Ͻ 0.01 and ***P Ͻ 0.001, agonist vs. control). 3 H]palmitic acid and then pretreated with 10 pM PD158780 for 5 min. Cells were then stimulated with 10 nM EGF for 30 min. Medium was harvested, and the lipids were separated by TLC. LPA was quantified using liquid scintillation counting. B: a similar experiment was carried out using 10 M 18:1 LPA as agonist. In A and B, data were normalized to the untreated controls and represent means Ϯ SE of values from triplicate wells of cells (*P Ͻ 0.05 and ***P Ͻ 0.001, agonist vs. control). C: OVCAR3 cells were incubated with 10 pM PD158780 for 5 min before addition of 10 nM EGF for 5 min. Whole cell extracts, equalized for protein, were immunoblotted for phospho-EGFR. All lanes are from the same experiment and were processed in parallel.
values for several lipid standards in this TLC system were as follows: LPA, 0.29; sphingosine-1-phosphate, 0.35; phosphatidic acid, 0.57; phosphatidylethanol (PEt), 0.74.
Intact membrane PLD activity assay. Cells were metabolically labeled with [ 3 H]palmitic acid (5 Ci/dish) for 12-24 h in serum-free medium. Before treatment, cells were washed twice with Dulbecco's modified Eagle's medium supplemented with 10 mM HEPES (pH 7.5) and were incubated in this medium at 37°C for 1 h. Cells were harvested following treatment with or without agonists in the presence of 0.5% ethanol. Lipids were extracted using methanol-HCl and chloroform, as previously described (41) . The lipids were dried under nitrogen. PA and PEt were added to each sample as standards. The samples were loaded on a TLC plate that was developed using ethyl acetate-acetic acid-water (90:20:100, vol/vol). The plate was exposed to X-ray film. Bands were scraped, and PLD activity was assessed following liquid scintillation spectrometry of PA, PEt, and the remainder of the lipid. Data are expressed as a percentage of total lipid recovered.
Statistical analysis. All experiments were repeated; representative results are shown. Statistics were determined by one-or two-way ANOVA using Graph-Pad InStat.
RESULTS
Effects of EGF on LPA production by ovarian cancer cells.
EGF and LPA are known to activate many of the same intracellular signaling pathways; LPA has been shown to transactivate the EGFR (22) . Conversely, to test whether a growth factor might transactivate LPA receptors, we first examined the effects of EGF on LPA production in ovarian cancer cells. Results obtained previously in our lab, using other cell lines, indicated that agonist-induced LPA production is most prominent in cell culture medium (40, 47) . Using a radioisotopic labeling assay, we analyzed LPA production by both OVCAR3 and SKOV3 cells (Fig. 1) . We examined effects of 10 nM EGF on LPA levels from 5 to 120 min. Lipids from the cells and the media were harvested separately. LPA levels increased in the medium as early as 15-30 min after EGF addition and were maximal at 60 -120 min (Fig. 1) . In the same experiment, LPA levels within the cells did not change significantly after EGF stimulation (data not shown). There results established that EGF stimulates LPA production in two human ovarian cancer cell lines.
Effects of EGFR inhibition on LPA production. EGF-induced LPA production is presumably mediated through EGFRmediated activation of phospholipases. To test whether EGFR activation correlated with increased LPA production, PD158780 (an EGFR-specific tyrosine kinase inhibitor) was used to block EGFR activation. OVCAR3 and SKOV3 cells were pretreated with 10 pM PD158780 for 5 min. The cells were then incubated with 10 nM EGF or 10 M 18:1 LPA for 30 min, and LPA production was measured. PD158780 blunted the EGFinduced increases in LPA levels in both cell lines (Fig. 2A) . Interestingly, the inhibitor also interfered with LPA-induced LPA production (Fig. 2B ). This result is consistent with im- munoblotting studies (data not shown) that indicated that both EGF and LPA induce tyrosine phosphorylation of the EGFR (Tyr992) in OVCAR3 and SKOV3 cells. As shown in Fig. 2C , immunoblotting confirmed that PD168780 inhibits EGFR phosphorylation under the conditions used. These data suggest that EGFR activity is necessary for LPA production.
Effects of pertussis toxin and LPA antagonist on LPA production. To address the potential for bidirectional cross-talk between receptors, we examined the role of LPARs in EGFinduced LPA production. PTX, an inhibitor of G ␣i and G ␣o , was used since PTX has already been shown to inhibit many LPA-induced effects (28, 47) . In Fig. 3A , SKOV3 cells were incubated with 100 ng/ml PTX overnight in serum-free medium. Cells were then incubated with 10 nM EGF or 10 M LPA for 30 min to assess LPA production. PTX inhibited LPA-induced LPA production, as expected, but also blocked EGF-induced LPA production. In Fig. 3B , the effects of PTX on EGF response were analyzed in the same experiment using both OVCAR3 and SKOV3 cells. PTX significantly inhibited EGF-induced LPA production in both cell lines, demonstrating that the effect is not unique to SKOV3. In Fig. 3C , the effects of an LPA receptor antagonist, Ki16425, were tested on LPA and EGF response in the two ovarian cancer cell lines. As shown, responses to both agonists were blocked by 10 M Ki16425. Taken together, these results suggest that both EGFR and LPARs are involved in EGF-induced LPA production. Only OVCAR3 cells were used for subsequent studies, since the agonist responses of the two cell lines were similar in the experiments shown in Figs. 1-3 .
Effects of PLA 2 inhibition on agonist-induced LPA production in ovarian cancer cells. The action of one or more forms of phospholipase A is assumed to be required for LPA production through any of the pathways discussed earlier, since LPA is a lysophospholipid. Previous unpublished data from our laboratory suggested the involvement of a calcium-independent form of PLA 2 in LPA production. We therefore tested for effects of arachidonyl trifluoromethyl ketone (AACOCF3), an inhibitor of cytosolic PLA 2 and calcium-independent PLA 2 (27), on LPA production. As shown in Fig. 4 , AACOCF3 inhibited LPA production induced by either LPA or EGF. From these results, we conclude that LPA production is dependent on PLA 2 activity.
Effects of PLD 2 overexpression on LPA production in ovarian cancer cells. PLD 2 is another enzyme that can be involved in LPA production, in combination with forms of phospholipase A. The EGFR has been shown to phosphorylate and colocalize with PLD 2 (7, 14, 33, 48) . As one approach to determine whether PLD 2 is involved with EGF-induced LPA production, we overexpressed PLD 2 in OVCAR3 cells using an expression vector encoding HA-tagged PLD 2 (16) . Cells were then serum starved; PLD activity was assessed using both a membrane (in vitro) PLD assay and an intact cell PLD assay. PLD 2 overexpression in OVCAR3 cells increased PLD activity, as measured by production of phosphatidylbutanol in the membrane assay (Fig. 5A) . In intact cells stimulated with 10 nM EGF for 15 min, PLD activity was significantly increased, as measured by PEt production (Fig. 5B) . Overexpression of PLD 2 in OVCAR3 cells also increased PEt production (Fig.  5B) . However, EGF did not further enhance PLD activity in cells overexpressing PLD 2 , perhaps indicating that maximal activity (as measured in this assay) had already been achieved.
Together, these data demonstrate that EGF, and PLD 2 overexpression, can increase PLD activity.
Effects of PLD 2 overexpression on LPA production were next examined. In OVCAR3 cells overexpressing PLD 2 , basal LPA production was increased twofold over control cells (Fig.  5C ). EGF did not further increase in LPA production in cells overexpressing PLD 2 , which may reflect a limit to the amount of LPA that can be produced. Together, these data suggest a role for PLD 2 in EGF-induced LPA production.
Effects of PLD 2 knockdown on EGF-induced LPA production. To further assess the role of PLD 2 in agonist-induced LPA production, we used a knockdown approach. OVCAR3 were incubated for 48 h with either 20 nM siRNA for PLD 2 , or with 20 nM nonsilencing siRNA. Cells were harvested and membranes prepared. In cells transfected with PLD 2 siRNA, membrane PLD 2 activity was markedly decreased (Fig. 6A) ; transfection with reagent alone or with nonsilencing siRNA had no effect. These results confirm that transfection with PLD 2 siRNA reduces membrane PLD 2 activity.
We next assessed the effects of PLD 2 siRNA on LPA production by OVCAR3. Cells were incubated with siRNA for PLD 2 siRNA blocked responses elicited by both LPA and EGF (Fig.  5B) , implicating PLD 2 in agonist-induced LPA production in OVCAR3 cells.
DISCUSSION
In this study we examined the role of EGF, a mitogenic agonist that binds to a tyrosine kinase receptor, on LPA production in ovarian cancer cells. Overexpression of EGFR is common in cancers, including 35-70% of ovarian cancers (10, 29) . The data demonstrate that EGF activation of the EGFR leads to increases in extracellular LPA. Substantial cross-talk between EGFR and LPARs is suggested by signal transduction studies using inhibitors of receptor response. Both the EGFR and LPARs are necessary for EGF-induced LPA production, suggesting cross-talk between receptors. The increase in LPA involves stimulation of PLD 2 .
This is the first study to show that EGF stimulates LPA production in ovarian cancer cells. A previous study of OVCAR-3 cells failed to demonstrate EGF-stimulated LPA production, possibly because only longer time points were examined (8) . The response observed in the current study can be blocked by inhibition of the EGFR, as expected. Interestingly, pertussis toxin also blocks EGF-stimulated LPA production, suggesting that cross-talk between receptors (tyrosine kinase and G protein-coupled receptors) is required. Such cross-talk could be mediated by downstream signaling pathways, or it could potentially reflect some type of interaction between the receptors themselves. LPA has already been shown to transactivate the EGFR, thus enlisting additional signaling pathways to amplify mitogenic responses. The current study demonstrates that such cross-talk also occurs in ovarian cancer cell lines. Moreover, we provide evidence that EGF-induced responses require LPARs. Acting in concert, LPA and EGF can potentially activate a plethora of intracellular signaling pathways.
LPA appears to accumulate in the extracellular space of carcinoma cells, such as in the ascites fluid surrounding ovarian tumors (39) . How LPA accumulates in the extracellular space is still unknown. LPA may be produced within the membrane and exported out of the cell, or it may be produced extracellularly. ATX, an extracellular enzyme, can produce LPA outside cells, and it is thus often considered responsible for extracellular LPA accumulation. While ATX does not seem to be responsible for agonist-induced LPA production under the experimental conditions used here (data not shown), there could still be other roles for ATX in ovarian cancer cells. In addition, since the relative contributions of basal and agoniststimulated LPA production to overall extracellular LPA levels are unknown, ATX or other lyso-PLDs likely play a major role in total LPA production in the in vivo environment.
LPPs, which hydrolyze LPA, play important roles in terminating LPA signaling (2, 35) . RT-PCR analysis showed that SKOV3 and OVCAR3 cells both express mRNA for LPP1 and LPP3 under the culture conditions used here (data not shown). Therefore, these enzymes are presumed to participate in LPA degradation. However, since the activities of these enzymes have not been shown to be regulated by agonists, it is unlikely that changes in LPP activity account for short-term agonistinduced changes in LPA levels in ovarian cancer cells.
PLD activity has been characterized in numerous mammalian cell lines (11) . PLDs can activated by small GTPases, receptor tyrosine kinases, and phosphatidylinositides (9, 17, 24, 25) . In this study, we show that PLD 2 activity is stimulated by EGF in ovarian cancer cells. PLD 2 was previously implicated in agonist-induced LPA production in SKOV3 cells, by another group of investigators (21) . However, this previous study did not link EGF to PLD-mediated LPA production.
LPA production by ovarian cancer cells can be stimulated by agonists such as phorbol 12-myristate 13-acetate (32) , which can also activate PLD 2 (11) . EGF has been shown to complex with PLD 2 , as well as to phosphorylate PLD 2 (34) . Dissociation of Munc-18-1, an inhibitory protein, from PLD 2 in response to EGF facilitates PLD 2 activation (19) . Protein kinase C (PKC) has also been shown to mediate EGF-induced stimulation of PLD (45) . Numerous signaling molecules including phospholipase C (13) and PKC (5, 13) have been shown to regulate EGF-mediated PLD 2 activation, both positively and negatively. Thus, there are multiple mechanisms potentially linking EGFR activation to PLD 2 .
While this study establishes roles for both PLA 2 and PLD 2 in agonist-induced LPA production, these roles are likely to be complex. PLA 2 may be involved in generating substrate for autotaxin, for example, or alternatively it may be needed to generate LPA from PA that is produced via the PLD reaction. PLD 2 may be directly involved in LPA production via formation of PA, or it may play other roles in facilitating receptormediated responses (e.g., via protein-protein interactions). These are areas for future study.
The evidence provided here concerning the role of PLD 2 in EGF-induced LPA production, along with the convergence of numerous signaling molecules on PLD 2 , suggests that PLD 2 is a potential therapeutic target in cancer. Further work is needed to determine the overall role of PLD 2 in intracellular and extracellular LPA production. Fig. 6 . Effects of PLD2 knockdown on EGF-induced LPA production. OVCAR3 were transfected with 20 nM small interfering RNA (siRNA) for PLD2, nonsilencing siRNA, or LF2000 alone for 48 h. A: cells were serum starved and harvested after 12 h. Membranes were separated with sonication and centrifugation. Membrane samples were incubated with butanol and B-PC for 60 min at 30°C. PLD products were separated by TLC and visualized by fluorescence imaging. Scr, scrambled. B: cells incubated with PLD2 siRNA or scrambled siRNA were metabolically labeled using [ 3 H]palmitic acid in serum-free medium and then incubated with or without 10 nM EGF or 10 M LPA for 30 min. Medium was harvested, and the lipids were separated and quantified. The values expressed were normalized to the untreated controls and represent means Ϯ SE for six experiments (**P Ͻ 0.01, EGF ϩ PLD2 siRNA vs. SCR siRNA control; *P Ͻ 0.05, LPA ϩ PLD2 siRNA vs. SCR siRNA control).
